A single-arm, prospective, multicenter, real-world study of efficacy and safety of fuquinitinib combined with capecitabine in maintenance therapy after first-line chemotherapy in metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Experimental group:The dose of fuquinitinib was 5mg, qd po, d1-14, q3w;The dose of capecitabine was 1000mg/m2, bid po, d1-14, q3w.
Primary outcome(s): Progression-free survival
Study Design: Single arm
DISEASE(S): Colorectal Cancer
PROVIDER: 89641 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA